Virbac Posts Strong H1 2026 Growth, Raises Full-Year Guidance…

Event summary

Virbac reported H1 2026 revenue growth of +7.4% at CERS, with companion animal segment up +10.0% and farm animal segment up +6.7%.
Adjusted EBIT margin reached 18.8%, a 0.5 percentage point increase from H1 2025, driven by favorable mix effects and price increases.
Consolidated net income rose +5.9% to €87.1 million, while net debt increased to €196 million due to seasonal working capital requirements.
Company confirmed 2026 guidance at the upper end of the range, targeting revenue growth of 5.5% to 7.5% and an adjusted recurring operating income margin of around 17%.

The big picture

Virbac's strong H1 2026 performance reflects broader trends in the animal health sector, where demand for companion animal products continues to outpace farm animal segments. The company's ability to integrate Thyronorm and scale its Supercharge platforms positions it well within a competitive landscape increasingly focused on operational efficiency and margin expansion. The raised guidance suggests confidence in sustaining this momentum, but investors will be watching for any signs of slowing growth or rising costs in the second half.

What we're watching

Revenue Sustainability: Whether Virbac can maintain its strong revenue growth in H2 2026, particularly in its high-growth Supercharge platforms.
Margin Management: How Virbac balances higher operating expenses with its favorable gross margin mix to sustain its elevated EBIT margin.
Debt Dynamics: The pace at which Virbac's net debt increases and whether it remains within manageable levels given its strong cash flow.